OpenAI Acquires Biopharma AI Startup Orchestra Bio, Team to Join Rosalind

OpenAI announced the acquisition of U.S. AI drug development collaboration platform Orchestra Bio, integrating its team and technology into its life sciences business Rosalind; the transaction amount was not disclosed. Founded in 2022, Orchestra provides R&D management software to biotech companies and pharmaceutical firms for setting R&D plans, managing budgets, and tracking project progress, and had raised $20 million in funding as of August 2025. OpenAI hopes to use this to build agents capable of coordinating drug development; its life sciences-specific model GPT-Rosalind ended its research preview in September and began billing on October 5.